OraSure Technologies, Inc. (NASDAQ:OSUR) Shares Bought by Barclays PLC

Barclays PLC lifted its holdings in shares of OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 182.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 195,793 shares of the medical instruments supplier's stock after acquiring an additional 126,503 shares during the quarter. Barclays PLC owned 0.26% of OraSure Technologies worth $836,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the business. Atom Investors LP purchased a new stake in OraSure Technologies during the 3rd quarter worth approximately $49,000. Creative Planning bought a new stake in shares of OraSure Technologies in the third quarter worth $54,000. Mackenzie Financial Corp acquired a new stake in OraSure Technologies in the second quarter valued at $72,000. Intech Investment Management LLC bought a new position in OraSure Technologies during the 3rd quarter valued at $84,000. Finally, SkyView Investment Advisors LLC grew its holdings in OraSure Technologies by 100.0% during the 2nd quarter. SkyView Investment Advisors LLC now owns 24,000 shares of the medical instruments supplier's stock worth $102,000 after acquiring an additional 12,000 shares in the last quarter. Institutional investors and hedge funds own 93.50% of the company's stock.

OraSure Technologies Stock Performance

Shares of NASDAQ OSUR traded up $0.01 during trading on Thursday, reaching $3.77. The stock had a trading volume of 485,847 shares, compared to its average volume of 820,542. The firm's 50 day moving average price is $3.83 and its two-hundred day moving average price is $4.10. OraSure Technologies, Inc. has a one year low of $3.52 and a one year high of $8.33. The stock has a market cap of $280.83 million, a PE ratio of 25.10 and a beta of 0.05.

OraSure Technologies (NASDAQ:OSUR - Get Free Report) last released its earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.02. OraSure Technologies had a net margin of 5.07% and a return on equity of 3.55%. The firm had revenue of $39.92 million during the quarter, compared to analyst estimates of $38.97 million. During the same quarter in the previous year, the firm earned $0.27 earnings per share. The firm's revenue for the quarter was down 55.2% compared to the same quarter last year. On average, research analysts expect that OraSure Technologies, Inc. will post -0.08 earnings per share for the current year.

Analysts Set New Price Targets

Separately, StockNews.com lowered shares of OraSure Technologies from a "buy" rating to a "hold" rating in a research note on Thursday, January 9th.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.